SciGen

What SciGen does

SciGen Pte. Ltd. is a Singapore-founded biopharmaceutical company established in 1998 that markets and commercializes innovative healthcare products worldwide across three segments: brand drugs, generics/biosimilars, and medical devices. The portfolio spans oncology supportive care (SciXeg pegfilgrastim biosimilar approved by both the FDA and EMA; SciLocyte filgrastim; Zometa zoledronic acid; HERI Thymosin α1; ISCADOR mistletoe extract; Zinc-S; NeoTrace 4), endocrinology (Diphereline GnRH agonist; Lorelin, the first GnRHa developed in Korea with international patent; SciTropin A recombinant human growth hormone), metabolic/insulin (Gensulin/SciLin European human insulin; Gensupen 2 delivery device), and medical devices (LTU-904 low-level laser for post-mastectomy lymphoedema). Revenue is generated through one-time product sales across multiple therapeutic areas, distributed via direct in-country sales teams (e.g., Korea country manager) and partner/distributor networks.

The company employs a sales-led go-to-market model targeting both established Asia-Pacific pharmaceutical markets (South Korea, Australia, Philippines, Singapore, Vietnam, Malaysia, Hong Kong, Thailand, Indonesia, New Zealand, Brunei, Taiwan) and emerging markets, leveraging regulatory credentials (FDA, EMA approvals) and partnership-based commercialization. Distribution operates through country-level management, a Pedi sales team, and channel partners such as Bioton for the Gensupen 2 device. The firm is privately held with no disclosed parent, institutional investors, or funding rounds, and its legal entity is domiciled in Singapore. Strategic differentiation rests on dual FDA/EMA regulatory approval for SciXeg, international patent protection for Lorelin, and a diversified multi-therapeutic, multi-geography portfolio that targets oncology, endocrine, and metabolic conditions with affordable branded and biosimilar alternatives.

Name

SciGen

Legal name

SciGen Pte. Ltd.

Website

https://scigenltd.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

SciGen Pte. Ltd. is a Singapore-founded biopharmaceutical company that markets and commercializes branded drugs, generics/biosimilars, and medical devices across oncology, endocrinology, and metabolic therapy areas in 12+ Asia-Pacific and emerging markets, supported by FDA and EMA regulatory approvals.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

Keywords

• Biopharmaceutical products
• Biosimilar development
• Oncology therapeutics
• Endocrinology treatments
• Medical devices

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Operations, Supply Chain, Personnel, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: SciGen markets and commercializes innovative healthcare products including brand drugs, generics/biosimilars, and medical devices. Revenue is generated through product sales across multiple therapeutic areas and geographic markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

SciGen is a biopharmaceutical company that markets and commercializes innovative healthcare products worldwide, focusing on three segments: Brand Drugs, Generics/Biosimilars, and Medical Devices. The portfolio spans oncology supportive care (pegfilgrastim biosimilar SciXeg, filgrastim SciLocyte, zoledronic acid Zometa, HERI Thymosin α1), endocrinology (GnRH agonists Diphereline and Lorelin, recombinant human growth hormone SciTropin A), metabolic disease (Gensulin/SciLin human insulin and Gensupen 2 delivery device), and medical devices (LTU-904 low-level laser for post-mastectomy lymphoedema). Products are commercialized across 12+ countries in Asia-Pacific and emerging markets through direct sales teams and distributor partnerships.

Product overview

SciGen is a Singapore-founded biopharmaceutical company that markets and commercializes innovative healthcare products worldwide across three segments: Brand Drugs, Generics/Biosimilars, and Medical Devices. The company's product portfolio includes oncology supportive care products (SciXeg® biosimilar pegfilgrastim, SciLocyte™ filgrastim, Zometa® zoledronic acid), endocrinology treatments (Diphereline® GnRH agonist, Lorelin GnRHa, SciTropin A™ rhGH), metabolic/insulin products (Gensulin®/SciLin™ human insulin, Gensupen 2® delivery device), trace element supplements (Zinc-S®, NeoTrace 4®), immune modulators (HERI® Thymosin α1, ISCADOR® mistletoe extract), and medical devices (LTU-904 low-level laser for lymphoedema). The portfolio aims to continuously fill and improve patient access to affordable healthcare products across global markets.

Differentiator

Problem solved

Functional benefit

Brands

• SciXeg: Biosimilar of pegfilgrastim in pre-filled syringe injection form, approved by FDA and EMA
• SciLocyte
• SciTropin A
• SciLin
• HERI
• NeoTrace 4

Products and services

• SciXeg Biosimilar of pegfilgrastim in pre-filled syringe injection form (6mg), approved by both FDA and EMA, providing G-CSF (granulocyte colony-stimulating factor) stimulation for oncology and hematology supportive care. Used to reduce infection incidence in patients receiving chemotherapy. Currently marketed in South Korea.
• SciLocyte G-CSF (granulocyte colony-stimulating factor) product offering efficacy and safety of filgrastim in pre-filled syringe format, used to increase absolute neutrophil count (ANC) in oncology patients. Currently marketed in the Philippines.
• Zometa Zoledronic acid product available in ready-to-use format for oncology applications including treatment of bone metastases and hypercalcemia of malignancy. Marketed across Australia, Brunei, Hong Kong, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.
• SciTropin A European quality ready-to-use recombinant human growth hormone (rhGH) for short stature correction, marketed in Asia-Pacific countries for pediatric endocrinology applications.
• Diphereline Prolonged-acting GnRH (gonadotropin-releasing hormone) agonist with proven efficacy and safety data since 1986 for endocrinology applications including treatment of hormone-responsive cancers, endometriosis, and central precocious puberty.
• Lorelin First GnRHa (gonadotropin-releasing hormone agonist) developed in Korea with international patent approval, used in endocrinology, oncology, and obstetrics/gynecology (OBGY) applications. Currently marketed in South Korea.
• Gensulin / SciLin High quality European human insulin product with 20 years of experience confirming effectiveness, safety and stability, used for diabetes management. Marketed in emerging markets.
• HERI Immune modulator containing Thymosin α1 to boost immune defense in immunocompromised patients, used in oncology supportive care. Currently marketed in South Korea.
• ISCADOR Swiss-made mistletoe (Viscum album) containing product for oncology support. Currently marketed in South Korea.
• Zinc-S Zinc sulfate hydrate product for prevention of low zinc levels in oncology patients. Molecule/API/MOA: Zinc sulfate hydrate. Currently marketed in South Korea.
• NeoTrace 4 Sterile, nonpyrogenic solution of zinc, copper, manganese, and chromium to prevent depletion of endogenous trace element stores and subsequent deficiency symptoms. Used in oncology supportive care. Currently marketed in South Korea.
• LTU-904 Innovative low-level laser treatment device for patients with Post-Mastectomy Lymphoedema. Currently marketed in South Korea.
• Gensupen 2 Insulin delivery device (injectable pharmaceutical product) with thousands of satisfied patients worldwide, partnered with Bioton. Marketed in emerging markets.

Quantifiable outcome

• Products marketed across 12+ countries including Australia, South Korea, Philippines, Singapore, and emerging markets

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Bioton (Gensupen 2)coreChannel Partner/ Reseller/ DistributorSciGen partners with Bioton for Gensupen 2 insulin delivery devices, which are currently marketed in emerging markets with thousands of satisfied patients worldwide. Gensupen 2 is highlighted as an injectable pharmaceutical product with established global patient base.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Biocon: Indian biopharmaceutical company with biosimilars (trastuzumab, pegfilgrastim, bevacizumab) approved in US/EU and emerging markets — most direct biosimilar competitive overlap with SciGen's SciXeg.
• Dr. Reddy's Laboratories: Indian-headquartered global generic and biosimilar company with established emerging-markets commercial infrastructure; comparable in product mix (biosimilars, generics, branded specialty).
• Hikma Pharmaceuticals: Specialty and generic pharmaceutical company with strong presence in Middle East and emerging markets; comparable commercialization model distributing across diverse therapeutic areas and geographies.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with biosimilars (including pegfilgrastim via partner) and global commercial reach; broader portfolio and scale than SciGen, but overlapping in therapeutic categories and emerging markets presence.
• LG Chem Life Sciences: Korean specialty pharma and biosimilar developer, comparable in geography and therapeutic focus, but with a much larger corporate parent and broader pipeline.

Direct peers

• Bioton: Polish biopharmaceutical company focused on human insulin and biotech products; SciGen's strategic partner for the Gensupen 2 insulin delivery device. Direct overlap in insulin/diabetes commercialization in emerging markets.
• Alvotech: Iceland-based pure-play biosimilar developer with FDA and EMA approvals, focused on oncology and autoimmune biosimilars. Comparable business model of biosimilar development targeting major regulated markets.
• Samsung Bioepis: Korean biosimilar company with multiple FDA/EMA approvals across oncology and immunology. Direct biosimilar peer competing for the same oncology supportive-care and biosimilar market segments as SciGen.
• Celltrion: South Korean biosimilar developer with FDA/EMA-approved biosimilars including Remsima (infliximab) and Herzuma (trastuzumab). Most directly comparable biosimilar competitor to SciGen's SciXeg and SciLocyte.

Regional players

• Nichi-Iko Pharmaceutical: Japan's largest generic pharmaceutical company; comparable in generics/biosimilars focus but primarily serves the Japanese domestic market rather than SciGen's Asia-Pacific/emerging markets footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SciGen